BLUETTI
12.3.2024 10:01:26 CET | Business Wire | Press release
BLUETTI, the leading innovator in sustainable energy solutions, is thrilled to announce the upcoming launch of its latest product, the BLUETTI AC200L Portable Power Station, set to hit the European market on March 13. Designed to revolutionize portable power, the AC200L is a powerhouse of reliability, efficiency, and eco-friendliness.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240312603366/en/
BLUETTI NEW COLLECTION AC200L (Photo: Business Wire)
Unrivaled Power and Durability
At the heart of the BLUETTI AC200L lies a robust 2,048Wh Lithium Iron Phosphate (LiFePO₄) battery, ensuring longevity and safety for over a decade with more than 3,000 life cycles. BLUETTI also backs it with an industry-leading 5-year warranty for added peace of mind. Equipped with a formidable 2,400W pure sine wave AC inverter(7,200W surge), extendable to 3,600W in Power Lifting mode, the AC200L is primed to handle high-demand appliances and sensitive electronics with ease.
Extendable Capacity and Fast Charging
The AC200L can independently power a 1,200W coffee maker, brewing about 31 cups of fresh coffee, and sustain a 150W fridge for over 12 hours. Additionally, it supports capacity expansion through extra batteries like the 2,048Wh B230 or two 3,072Wh B300 battery packs. This boosts its capacity to 4,096Wh or 8,192Wh, respectively, prolonging its runtime as required.
With 2,400W of fast charge capability, the AC200L can reach an 80% charge from the wall in as little as 45 minutes. In optimal weather conditions, it completes a 1,200W solar charge in approximately 2 hours, perfect for backup and on-the-go power needs.
Versatile Outlets and Intelligent Features
The AC200L boasts 10 outlets for diverse power needs, including a 48V DC port for RV life battery charging when paired with the optional BLUETTI D40 DC-DC charger, which can convert 12V power for most RV devices.
Moreover, users can adjust these settings and monitor/manage the battery via the BLUETTI app.
About BLUETTI
Committed to a sustainable future, BLUETTI has pioneered affordable green energy storage solutions for both indoor and outdoor use. Through initiatives like the LAAF (Lighting An African Family) program, BLUETTI will empower over 100,000 African families in rural areas, providing well-lit living spaces and equal learning opportunities. With an extensive and reliable product portfolio tailored for adventures, emergency backup power, and off-grid living, BLUETTI continues to make a tangible and positive impact on minimizing our carbon footprint worldwide. For more information on BLUETTI and its innovative products, visit BLUETTI's website.
Source: BLUETTI EU Marketing
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240312603366/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom